FDA greenlights Celltrion HIV drug manufacturing facility in South Korea
South Korean biopharma firm Celltrion has revealed that one of its key manufacturing facilities has been given the all-clear by the FDA following an on-site inspection in January.
The visit to the site in Cheongju, the largest city in the nation’s North Chungcheong Province, was for an additional inspection in order to review new technology which was omitted in the facility’s most recent Current Good Manufacturing Practice (CGMP) report, with the FDA finding no issues requiring intervention.
Among the products manufactured at the facility is the drugmaker’s three-in-one oral treatment for HIV, known as CT-G07, which is currently awaiting approval from the FDA for commercialisation in the US. Celltrion is hoping for a decision as early as April this year.
Nexcella has announced that the US Food and Drug Administration (FDA) has granted orphan drug …
GSK has announced that the US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) …